RE: +10 %25 Nov 2025 11:28
It’s just matter of time , there is a clear demand out there and GDR has the test which no one have at the moment .
https://allen.silverchair-cdn.com/allen/content_public/journal/aplm/pap/10.5858_arpa.2025-0179-cp/2/10.5858_arpa.2025-0179-cp.pdf
“ At most institutions
today, PGx results are not readily available at the time of
prescription. Many clinicians are not eager to delay medical
therapy to wait for PGx test results, particularly for medications
like clopidogrel, warfarin, or fluoropyrimidines.38–42 Thus, to
meet the clinical TAT requirements of reactive PGx testing, the
laboratory may need to develop rapid workflows for ordering,
sample collection, testing, and result return. Mitochondrially
encoded 12S rRNA [MT-RNR1] testing to guide use of amino-
glycosides for neonatal sepsis is one example in which a quick
TAT is required.43 When sepsis is suspected in a neonate, an
aminoglycoside antibiotic is typically administered within the
next hour. However, patients who have a mitochondrial MT-
RNR1 variant are at increased risk of aminoglycoside-induced
hearing loss. If a test result for MT-RNR1 is not available
quickly, it will not have utility in this setting. Similarly, cyto-
chrome P450 family 2 subfamily C member 19 [CYP2C19]
results are desired quickly in the setting of acute coronary
syndromes and stroke in order to guide choice of oral
P2Y12 inhibitor therapy.39,42 In the absence of CYP2C19
loss-of-function variants, clopidogrel is a cost-effective
option. If testing cannot be performed quickly enough,
PGx may be bypassed by choosing a P2Y12 inhibitor that
is not activated by CYP2C19; however, many of these
alternatives are more expensive and are more potent,
which may increase the risk of bleeding complications. For
both MT-RNR1 and CYP2C19, rapid tests are desirable
and have been implemented at some centers.43–45 Failure
to understand clinical management expectations before
implementing PGx testing may jeopardize adoption.46 TAT
requirements may be less strict for preemptive testing and
for medications used for less life-threatening conditions”
Sign In
Follow the stocks
